Journal Article

Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor

M. Gross, J. Clements, R. P. Beckett, W. Thomas, S. Taylor, D. Lofland, S. Ramanathan-Girish, M. Garcia, S. Difuntorum, U. Hoch, H. Chen and K. W. Johnson

in Journal of Antimicrobial Chemotherapy

Published on behalf of British Society for Antimicrobial Chemotherapy

Volume 53, issue 3, pages 487-493
Published in print March 2004 | ISSN: 0305-7453
Published online March 2004 | e-ISSN: 1460-2091 | DOI:
Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor

More Like This

Show all results sharing these subjects:

  • Medical Oncology
  • Critical Care


Show Summary Details


Objective: BB-81384, a novel peptide deformylase (PDF) inhibitor, was characterized in terms of enzyme inhibition profile, antibacterial activity, rodent pharmacokinetics and oral efficacy in murine infection models.

Methods: MICs were determined by standard NCCLS broth microdilution. Selectivity of metalloenzyme inhibition was determined with a limited panel of enzymes via standard biochemical assays. Profiling of the pharmacokinetics and select tissue disposition in mice was determined and compared with that of the macrolide, azithromycin. In vivo murine efficacy studies using Streptococcus pneumoniae were conducted using a peritonitis model, as well as lung and thigh burden models of infection.

Results: BB-81384 selectively inhibited PDF with an IC50 ∼10 nM and with MICs < 0.5 mg/L against most S. pneumoniae pathogens. Pharmacokinetic analysis revealed good oral bioavailability and moderate clearance and volume of distribution. BB-81384 partitioning to lung tissue was similar in terms of magnitude and kinetics to that of the plasma compartment. Single-administration oral efficacy in a mouse peritonitis model was evident with an ED50 of 30 mg/kg. BB-81384 reduced the bacterial load by ∼5 and 3 log units in organ-burden models of lung and thigh infection, respectively.

Conclusion: BB-81384, a novel PDF inhibitor with good activity against S. pneumoniaein vitro, was the first compound of this class to be profiled for oral pharmacokinetics and tissue disposition and to demonstrate oral anti-pneumococcal efficacy in mice.

Keywords: Keywords: peptide deformylase, efficacy, pharmacokinetics

Journal Article.  4721 words.  Illustrated.

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.